Amneal Pharmaceuticals Inc (NYSE:AMRX) SVP Pradeep Bhadauria bought 7,000 shares of the stock in a transaction dated Wednesday, May 15th. The stock was purchased at an average price of $8.48 per share, with a total value of $59,360.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
AMRX stock traded down $0.15 on Friday, reaching $8.57. 778,044 shares of the company traded hands, compared to its average volume of 1,008,019. Amneal Pharmaceuticals Inc has a one year low of $8.23 and a one year high of $24.48. The company has a quick ratio of 1.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.44. The firm has a market cap of $2.60 billion, a PE ratio of 9.02, a price-to-earnings-growth ratio of 0.51 and a beta of 1.31.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.07). Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The company had revenue of $446.00 million for the quarter, compared to the consensus estimate of $438.18 million. The firm’s revenue was up 4.9% on a year-over-year basis. On average, research analysts expect that Amneal Pharmaceuticals Inc will post 0.95 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of AMRX. Bank of New York Mellon Corp increased its position in Amneal Pharmaceuticals by 5.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 494,535 shares of the company’s stock valued at $10,973,000 after buying an additional 27,206 shares in the last quarter. Jane Street Group LLC bought a new position in Amneal Pharmaceuticals during the 3rd quarter valued at approximately $249,000. TIAA CREF Investment Management LLC increased its position in Amneal Pharmaceuticals by 38.2% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 349,925 shares of the company’s stock valued at $7,765,000 after buying an additional 96,813 shares in the last quarter. Legal & General Group Plc increased its position in Amneal Pharmaceuticals by 20.7% during the 3rd quarter. Legal & General Group Plc now owns 32,695 shares of the company’s stock valued at $726,000 after buying an additional 5,596 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Amneal Pharmaceuticals by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 9,207,978 shares of the company’s stock valued at $204,326,000 after buying an additional 465,375 shares in the last quarter. 38.31% of the stock is owned by institutional investors.
AMRX has been the subject of a number of research analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $35.00 target price on shares of Amneal Pharmaceuticals in a research note on Thursday, February 28th. Leerink Swann cut Amneal Pharmaceuticals to a “market perform” rating in a research note on Friday, March 8th. Svb Leerink cut Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $16.00 to $12.00 in a research note on Friday, March 8th. SunTrust Banks initiated coverage on Amneal Pharmaceuticals in a research note on Tuesday, March 19th. They issued a “buy” rating and a $16.00 target price for the company. Finally, ValuEngine cut Amneal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, April 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company’s stock. Amneal Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $20.10.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Recommended Story: Book Value Per Share in Stock Trading
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.